Can Zoledronic Acid be Beneficial for Promoting Tumor Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy?

The antitumor effect of bisphosphonates (BPs) is under increasing scrutiny. Preclinical and clinical evidence has shown that BPs might sensitize breast tumors to chemotherapy. Here, we present a review of current preclinical and clinical evidence for antitumor effects of BPs, and evaluate how BPs mi...

Descripción completa

Detalles Bibliográficos
Autores principales: Charehbili, Ayoub, Fontein, Duveken B. Y., Kroep, Judith R., Liefers, Gerrit-Jan, Nortier, Johannes W. R., van de Velde, Cornelis J. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470143/
https://www.ncbi.nlm.nih.gov/pubmed/26237143
http://dx.doi.org/10.3390/jcm2040188
Descripción
Sumario:The antitumor effect of bisphosphonates (BPs) is under increasing scrutiny. Preclinical and clinical evidence has shown that BPs might sensitize breast tumors to chemotherapy. Here, we present a review of current preclinical and clinical evidence for antitumor effects of BPs, and evaluate how BPs might play a role in neoadjuvant treatment of women with breast cancer.

Ejemplares similares